Samuel G. Johnson

2.2k total citations · 1 hit paper
36 papers, 1.3k citations indexed

About

Samuel G. Johnson is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Geriatrics and Gerontology. According to data from OpenAlex, Samuel G. Johnson has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 8 papers in Economics and Econometrics and 7 papers in Geriatrics and Gerontology. Recurrent topics in Samuel G. Johnson's work include Atrial Fibrillation Management and Outcomes (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Pharmaceutical Practices and Patient Outcomes (7 papers). Samuel G. Johnson is often cited by papers focused on Atrial Fibrillation Management and Outcomes (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Pharmaceutical Practices and Patient Outcomes (7 papers). Samuel G. Johnson collaborates with scholars based in United States, Finland and Sweden. Samuel G. Johnson's co-authors include Teri E. Klein, Li Gong, Laura B. Ramsey, Whitney D. Maxwell, Mikko Niemi, Mia Wadelius, Deepak Voora, Russell A. Wilke, Ronald M. Krauss and Howard L. McLeod and has published in prestigious journals such as CHEST Journal, Clinical Pharmacology & Therapeutics and Current Opinion in Pharmacology.

In The Last Decade

Samuel G. Johnson

36 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

2014 301 citations Laura B. Ramsey, Samuel G. Johnson et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel G. Johnson United States	18	532	281	261	223	192	36	1.3k
Whitney D. Maxwell United States	11	288 0.5×	144 0.5×	231 0.9×	91 0.4×	92 0.5×	21	868
Sony Tuteja United States	20	283 0.5×	198 0.7×	320 1.2×	229 1.0×	109 0.6×	71	1.3k
Andrea H. Ramirez United States	20	482 0.9×	263 0.9×	137 0.5×	329 1.5×	446 2.3×	41	1.7k
Jung Mi Oh South Korea	24	182 0.3×	379 1.3×	215 0.8×	112 0.5×	93 0.5×	139	1.7k
Johannes Mulder Netherlands	9	718 1.3×	329 1.2×	178 0.7×	84 0.4×	126 0.7×	21	1.1k
Matthijs L. Becker Netherlands	21	256 0.5×	243 0.9×	439 1.7×	288 1.3×	92 0.5×	62	1.8k
J. Russell Teagarden United States	15	258 0.5×	112 0.4×	109 0.4×	309 1.4×	99 0.5×	44	1.0k
DM Roden United States	7	312 0.6×	196 0.7×	81 0.3×	136 0.6×	278 1.4×	8	1.1k
Lori A. Orlando United States	26	150 0.3×	137 0.5×	345 1.3×	233 1.0×	549 2.9×	80	1.8k
Carmen Ferrajolo Italy	24	135 0.3×	258 0.9×	201 0.8×	89 0.4×	53 0.3×	56	1.4k

Countries citing papers authored by Samuel G. Johnson

Since Specialization

Citations

This map shows the geographic impact of Samuel G. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel G. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel G. Johnson more than expected).

Fields of papers citing papers by Samuel G. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel G. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel G. Johnson. The network helps show where Samuel G. Johnson may publish in the future.

Co-authorship network of co-authors of Samuel G. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel G. Johnson. A scholar is included among the top collaborators of Samuel G. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel G. Johnson. Samuel G. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, Samuel G.. (2019). Role of board certification in advancing pharmacy practice. Pharmacy Practice. 17(4). 1767–1767. 9 indexed citations

Rivkin, Inna, et al.. (2018). Cultural values, coping, and hope in Yup'ik communities facing rapid cultural change. Journal of Community Psychology. 47(3). 611–627. 12 indexed citations

Johnson, Samuel G., et al.. (2017). Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharmacy Practice. 15(2). 946–946. 9 indexed citations

Maxwell, Whitney D., et al.. (2017). Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 37(9). 1172–1190. 24 indexed citations

Baker, William L. & Samuel G. Johnson. (2016). Pharmacogenetics and oral antithrombotic drugs. Current Opinion in Pharmacology. 27. 38–42. 21 indexed citations

Witt, Daniel M., Thomas Delate, Samuel G. Johnson, et al.. (2015). Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thrombosis Research. 136(6). 1160–1164. 17 indexed citations

Beachy, Sarah H., Samuel G. Johnson, Steve Olson, & Adam C. Berger. (2014). Drug Repurposing and Repositioning: Workshop Summary. 2 indexed citations

Clancy, John P., Samuel G. Johnson, Sook Wah Yee, et al.. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype. Clinical Pharmacology & Therapeutics. 95(6). 592–597. 41 indexed citations

Irwin, Adriane N., et al.. (2014). A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. Thrombosis Research. 133(5). 790–794. 2 indexed citations

10.

Gubbins, Paul O., Scott T. Micek, Melissa E. Badowski, et al.. (2014). Innovation in Clinical Pharmacy Practice and Opportunities for Academic–Practice Partnership. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 34(5). e45–54. 30 indexed citations

11.

Ramsey, Laura B., Samuel G. Johnson, Kelly E. Caudle, et al.. (2014). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology & Therapeutics. 96(4). 423–428. 301 indexed citations breakdown →

12.

Johnson, Samuel G., et al.. (2013). Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system. Journal of Medical Economics. 16(12). 1414–1422. 13 indexed citations

13.

Koo, Kevin, et al.. (2013). Patient Education Level and Utilization of Internet Resources by Patients in Orthopedic Hip and Knee Consultations. 2(1). 54–60. 4 indexed citations

14.

Muir, Andrew J., Li Gong, Samuel G. Johnson, et al.. (2013). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens. Clinical Pharmacology & Therapeutics. 95(2). 141–146. 65 indexed citations

15.

Wilke, Russell A., Laura B. Ramsey, Samuel G. Johnson, et al.. (2012). The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clinical Pharmacology & Therapeutics. 92(1). 112–117. 242 indexed citations

16.

Johnson, Samuel G.. (2009). Improving Cost-Effectiveness of and Outcomes From Drug Therapy in Patients With Atrial Fibrillation in Managed Care: Role of the Pharmacist. Journal of Managed Care Pharmacy. 15(6 Supp B). 19–25. 11 indexed citations

17.

Olson, Kari L., et al.. (2009). Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. 29(3). 316–321. 15 indexed citations

18.

Johnson, Samuel G., et al.. (2008). Outcomes Associated With Combined Antiplatelet and Anticoagulant Therapy. CHEST Journal. 133(4). 948–954. 56 indexed citations

19.

Johnson, Samuel G.. (2008). Known knowns and known unknowns: Risks associated with combination antithrombotic therapy. Thrombosis Research. 123. S7–S11. 22 indexed citations

20.

Johnson, Samuel G., et al.. (2005). An Examination of the Association Between Therapeutic Anticoagulation Control and Glycemic Control for Patients with Diabetes on Oral Anticoagulation Therapy. Journal of Thrombosis and Thrombolysis. 19(3). 209–212. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact